ITIF's Center for Data Innovation released a new report exploring opportunities to accelerate data-driven innovation in drug development and hosted a panel discussion about the ways data can make drug development faster, more efficient, and lead to new cures.
ITIF released a new report laying out a productivity-focused agenda for federal science and engineering research, and a panel explored how increasing government spending on R&D can help advance technology, boost productivity, and improve living standards.
ITIF's Center for Data Innovation hosted a keynote address by Michael Kratsios, Chief Technology Officer of the United States, and a panel discussion on the state of the global AI race and how policymakers can continue to support U.S. leadership in AI.
ITIF hosted a discussion about the benefits of using facial recognition for law enforcement and public safety, the current safeguards in place that govern its use, and the opportunities for policymakers to address legitimate concerns without limiting the potential of this technology.
ITIF hosted an expert panel discussion on the current state and future potential of robotics across all sectors of the U.S. economy.
ITIF hosted an expert panel to discuss growing calls to either break up big tech companies or subject them to more careful scrutiny out of concern they may be violating competition laws. The panel examined these issues and explored what, if anything, should be done to change the current antitrust regime.
ITIF hosted a spirited debate about the fraught economic political realities of the U.S.-China trading relationship and the best-available options for policymakers.
ITIF's Center for Data Innovation hosted a panel discussion on the opportunities for collaboration on AI between Canada, the European Union, and the United States.
ITIF hosted an expert panel discussion marking the release of a new report that examines the deep trade interlinkages and value-added trade flows between the United States, Mexico, Korea, and Taiwan across six high-tech sectors: automobiles, chemicals, computers and electronics, machinery, aerospace and other transportation equipment, and pharmaceuticals.
ITIF hosted an expert panel discussion on impact drug-price controls have and what effect, if any, mandated drug-price reductions would have on biopharmaceutical innovation and U.S. industry competitiveness.